Key Takeaways
- Global biotech sector up by 1.1% last week, but has on the whole remained relatively stable over the last two quarters.
- 10 months into 2024, venture rounds are higher in valuation and lower in frequency.
- 2024 biopharma licensing deals are lagging behind previous years:
- RNA therapeutics, Degraders and Vaccine modalities have done will among listed biotech, and obesity remains strong
- Oncology and neuro still lead in licensing and partnership activity